icon-    folder.gif   Conference Reports for NATAP  
  (APASL) 25th Conference of the Asian Pacific
Association for the Study of the Liver
Feb 20-24 2016, Tokyo, Japan

Back grey_arrow_rt.gif
All-Oral Daclatasvir/Asunaprevir/Beclabuvir Fixed-Dose Combination Therapy for HCV Genotype 1..... Enrolled in South Korea, Taiwan, and Russia.....mostly HCV GT 1b infection, up to 20% with compensated cirrhosis
  Reported by Jules Levin
25th Conference of the Asian Pacific Association for the Study of the Liver: APASL 2016, Tokyo, Japan
Kao J-H,1 Yu M-L,2 Peng C-Y,3 Heo J,4 Chu C-J,5 Chang T-T,6 Lee Y-J,7 Hu T-H,8 Yoon KT,9 Paik SW,10 Lim YS,11 Ahn S-H,12 Isakov V,13 McPhee F,14 Hu W,14 Swenson ES,14 Yin PD,14 Treitel M14
1National Taiwan University College of Medicine, Taipei, Taiwan; 2Kaohsiung Medical University, Kaohsiung, Taiwan; 3China Medical University Hospital, Taichung, Taiwan; 4Pusan National University College of Medicine, Busan, Republic of Korea; 5Taipei Veterans General Hospital, Taipei, Taiwan; 6National Cheng Kung University Hospital, Tainan, Taiwan; 7Inje University Busan Paik Hospital, Busan, Republic of Korea, 8Chang Gung Memorial Hospital-Kaohsiung Medical Center, Taiwan; 9Pusan National University Yangsan Hospital, Busan, Republic of Korea; 10Samsung Medical Center, Seoul, Republic of Korea; 11Asan Medical Center, Seoul, Republic of Korea; 12Yonsei University College of Medicine, Seoul, Republic of Korea; 13Science Research Institute of Nutrition, Moscow, Russia; 14Bristol-Myers Squibb, Princeton, NJ, USA.